147 related articles for article (PubMed ID: 38244928)
1. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Harvey-Jones E; Raghunandan M; Robbez-Masson L; Magraner-Pardo L; Alaguthurai T; Yablonovitch A; Yen J; Xiao H; Brough R; Frankum J; Song F; Yeung J; Savy T; Gulati A; Alexander J; Kemp H; Starling C; Konde A; Marlow R; Cheang M; Proszek P; Hubank M; Cai M; Trendell J; Lu R; Liccardo R; Ravindran N; Llop-Guevara A; Rodriguez O; Balmana J; Lukashchuk N; Dorschner M; Drusbosky L; Roxanis I; Serra V; Haider S; Pettitt SJ; Lord CJ; Tutt ANJ
Ann Oncol; 2024 Apr; 35(4):364-380. PubMed ID: 38244928
[TBL] [Abstract][Full Text] [Related]
2. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
Zong H; Zhang J; Xu Z; Pan JN; Wang R; Han J; Jiang M; Ren R; Zang L; Wang H; Cao WM
J Cancer; 2022; 13(4):1119-1129. PubMed ID: 35281878
[No Abstract] [Full Text] [Related]
4. Clinical
Pettitt SJ; Frankum JR; Punta M; Lise S; Alexander J; Chen Y; Yap TA; Haider S; Tutt ANJ; Lord CJ
Cancer Discov; 2020 Oct; 10(10):1475-1488. PubMed ID: 32699032
[TBL] [Abstract][Full Text] [Related]
5. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
6. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV
Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561
[TBL] [Abstract][Full Text] [Related]
7. Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
Yndestad S; Engebrethsen C; Herencia-Ropero A; Nikolaienko O; Vintermyr OK; Lillestøl RK; Minsaas L; Leirvaag B; Iversen GT; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Aase HS; Aas T; Gudlaugsson EG; Llop-Guevara A; Serra V; Janssen EAM; Lønning PE; Knappskog S; Eikesdal HP
JCO Precis Oncol; 2023 Sep; 7():e2300338. PubMed ID: 38039432
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
10. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
[TBL] [Abstract][Full Text] [Related]
11. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
[TBL] [Abstract][Full Text] [Related]
12. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
13. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
14. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
[TBL] [Abstract][Full Text] [Related]
15.
Velazquez C; Orhan E; Tabet I; Fenou L; Orsetti B; Adélaïde J; Guille A; Thézénas S; Crapez E; Colombo PE; Chaffanet M; Birnbaum D; Sardet C; Jacot W; Theillet C
Front Oncol; 2023; 13():1125021. PubMed ID: 37007122
[TBL] [Abstract][Full Text] [Related]
16. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.
Sztupinszki Z; Diossy M; Krzystanek M; Borcsok J; Pomerantz MM; Tisza V; Spisak S; Rusz O; Csabai I; Freedman ML; Szallasi Z
Clin Cancer Res; 2020 Jun; 26(11):2673-2680. PubMed ID: 32071115
[TBL] [Abstract][Full Text] [Related]
17.
Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
[No Abstract] [Full Text] [Related]
18. Homologous Recombination Abnormalities Associated With
Albitar M; Zhang H; Pecora A; Waintraub S; Graham D; Hellmann M; McNamara D; Charifa A; De Dios I; Ma W; Goy A
Breast Cancer (Auckl); 2023; 17():11782234231198979. PubMed ID: 37789896
[TBL] [Abstract][Full Text] [Related]
19. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
[TBL] [Abstract][Full Text] [Related]
20. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL
J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
